Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinisches Magazin

05.02.2025 | Pathologie

SARIFA – ein neuer entitätenübergreifender Biomarker

verfasst von: Bianca Grosser, Nic G. Reitsam, Przmyslaw Grochowski, Lukas Rentschler, Johanna Enke, Prof. Dr. Bruno Märkl

Erschienen in: Wiener klinisches Magazin

Einloggen, um Zugang zu erhalten

Zusammenfassung

SARIFA (Akronym für „Stroma Areactive Invasion Front Areas“) ist ein neuer prognostischer Biomarker in Karzinomen. Im Wesentlich beschreibt SARIFA das Auftreten eines direkten Kontakts von mindestens 5 Tumorzellen mit ortsständigen Fettzellen. Dieses Phänomen ist einfach und schnell zu bestimmen, zeigt eine äußerst niedrige Interobservervariabilität und erfordert, da an üblichen HE-Schnitten identifizierbar, keinerlei Zusatzfärbungen. Die prognostische Effizienz wurde mittlerweile an Magen‑, Pankreas- und Prostatakarzinom sowie an kolorektalen Karzinomen nachgewiesen.
Literatur
1.
Ahn S, Lee SJ, Kim Y et al (2017) High-throughput Protein and mRNA Expression-based Classification of Gastric Cancers Can Identify Clinically Distinct Subtypes, Concordant With Recent Molecular Classifications. Am J Surg Pathol 41:106–115CrossRefPubMed
2.
3.
Butler LM, Perone Y, Dehairs J et al (2020) Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev 159:245–293CrossRefPubMedPubMedCentral
4.
5.
Duong MN, Geneste A, Fallone F et al (2017) The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance. Oncotarget 8:57622–57641CrossRefPubMedPubMedCentral
6.
Enke JS, Gross M, Grosser B et al (2024) SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer. BMC Cancer 24:65CrossRefPubMedPubMedCentral
7.
Foersch S, Glasner C, Woerl AC et al (2023) Multistain deep learning for prediction of prognosis and therapy response in colorectal cancer. Nat Med 29:430–439CrossRefPubMed
8.
Foersch S, Lang-Schwarz C, Eckstein M et al (2022) pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas-proposal for a new pT3a/pT3b subclassification. Br J Cancer 127:1270–1278CrossRefPubMedPubMedCentral
9.
Grochowski P, Grosser B, Sommer F et al (2024) The Concept of Stroma AReactive Invasion Front Areas (SARIFA) as a new prognostic biomarker for lipid-driven cancers holds true in pancreatic ductal adenocarcinoma. BMC Cancer 24:768CrossRefPubMedPubMedCentral
10.
Grosser B, Emmerson J, Reitsam NG et al (2023) Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial. Br J Cancer 130:457–466CrossRefPubMedPubMedCentral
11.
Grosser B, Glückstein MI, Dhillon C et al (2022) Stroma AReactive Invasion Front Areas (SARIFA)—a new prognostic biomarker in gastric cancer related to tumor-promoting adipocytes. J Pathol 256:71–82CrossRefPubMed
12.
Grosser B, Heyer CM, Austgen J et al (2023) Stroma AReactive Invasion Front Areas (SARIFA) proves prognostic relevance in gastric carcinoma and is based on a tumor-adipocyte interaction indicating an altered immune response. Gastric Cancer 27:72–85CrossRefPubMedPubMedCentral
13.
Grosser B, Schiele S, Reitsam NG et al (2024) SARIFA, a new prognostic histomorphological biomarker in gastric cancer identifies cases with a distinct biology—a post hoc analysis of the ST03 trial. Oncol Res Treat 26:26
14.
Guerrero-Rodríguez SL, Mata-Cruz C, Pérez-Tapia SM et al (2022) Role of CD36 in cancer progression, stemness, and targeting. Front Cell Dev Biol 10:1079076CrossRefPubMedPubMedCentral
15.
16.
Guo Y, Wang ZW, Su WH et al (2020) Prognostic Value and Immune Infiltrates of ABCA8 and FABP4 in Stomach Adenocarcinoma. Biomed Res Int 2020:4145164CrossRefPubMedPubMedCentral
17.
Kim HS, Kim KM, Lee SB et al (2019) Clinicopathological and biomolecular characteristics of stage IIB/IIC and stage IIIA colon cancer: Insight into the survival paradox. J Surg Oncol 120:423–430CrossRefPubMed
18.
Koundouros N, Poulogiannis G (2020) Reprogramming of fatty acid metabolism in cancer. Br J Cancer 122:4–22CrossRefPubMed
19.
Lengyel E, Makowski L, Digiovanni J et al (2018) Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors. Trends Cancer 4:374–384CrossRefPubMedPubMedCentral
20.
21.
Martin B, Grosser B, Kempkens L et al (2021) Stroma AReactive Invasion Front Areas (SARIFA)—A New Easily to Determine Biomarker in Colon Cancer-Results of a Retrospective Study. Cancers 13:
22.
Mukherjee A, Bilecz AJ, Lengyel E (2022) The adipocyte microenvironment and cancer. Cancer Metastasis Rev 41:575–587CrossRefPubMed
23.
Mukherjee A, Chiang CY, Daifotis HA et al (2020) Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance. Cancer Res 80:1748–1761CrossRefPubMedPubMedCentral
24.
Offermans K, Reitsam NG, Simons C et al (2024) The relationship between Stroma AReactive Invasion Front Areas (SARIFA), Warburg-subtype and survival: results from a large prospective series of colorectal cancer patients. Cancer Metab 12:21CrossRefPubMedPubMedCentral
25.
Reitsam NG, Grosser B, Enke JS et al (2024) Stroma AReactive Invasion Front Areas (SARIFA): a novel histopathologic biomarker in colorectal cancer patients and its association with the luminal tumour proportion. Transl Oncol 44:101913CrossRefPubMedPubMedCentral
26.
Reitsam NG, Grozdanov V, Loffler CML et al (2024) Novel biomarker SARIFA in colorectal cancer: highly prognostic, not genetically driven and histologic indicator of a distinct tumor biology. Cancer Gene Ther 31:207–216CrossRefPubMed
27.
Reitsam NG, Märkl B, Dintner S et al (2023) Alterations in Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA). Cancers 15:
28.
Setia N, Agoston AT, Han HS et al (2016) A protein and mRNA expression-based classification of gastric cancer. Mod Pathol 29:772–784CrossRefPubMed
29.
Tang Z, Shen Q, Xie H et al (2016) Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC). Oncotarget 7:46253–46262CrossRefPubMedPubMedCentral
30.
Ulase D, Behrens HM, Röcken C (2024) Stroma AReactive Invasion Front Areas (SARIFA) predict poor survival in adenocarcinomas of the stomach and gastrooesophageal junction: a validation study. Virchows Arch
31.
Vasseur S, Guillaumond F (2022) Lipids in cancer: a global view of the contribution of lipid pathways to metastatic formation and treatment resistance. Oncogenesis 11:46CrossRefPubMedPubMedCentral
32.
Wen YA, Xing X, Harris JW et al (2017) Adipocytes activate mitochondrial fatty acid oxidation and autophagy to promote tumor growth in colon cancer. Cell Death Dis 8:e2593CrossRefPubMedPubMedCentral
33.
Wulczyn E, Steiner DF, Moran M et al (2021) Interpretable survival prediction for colorectal cancer using deep learning. NPJ Digit Med 4:71CrossRefPubMedPubMedCentral
34.
Yang K, Lu HH, Zhao W et al (2023) Efficacy and safety of metformin in combination with chemotherapy in cancer patients without diabetes: systematic review and meta-analysis. Front Oncol 13:1176885CrossRefPubMedPubMedCentral
Metadaten
Titel
SARIFA – ein neuer entitätenübergreifender Biomarker
verfasst von
Bianca Grosser
Nic G. Reitsam
Przmyslaw Grochowski
Lukas Rentschler
Johanna Enke
Prof. Dr. Bruno Märkl
Publikationsdatum
05.02.2025
Verlag
Springer Vienna
Erschienen in
Wiener klinisches Magazin
Print ISSN: 1869-1757
Elektronische ISSN: 1613-7817
DOI
https://doi.org/10.1007/s00740-025-00548-4